IDEXX Laboratories Sees Significant Increase in Institutional Ownership

Congress Asset Management Co. boosts stake in veterinary diagnostics company by nearly 10,000%

Mar. 24, 2026 at 8:38am

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Congress Asset Management Co. increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9,894% during the 4th quarter. The fund now owns 153,908 shares of the company's stock, representing a significant boost in institutional ownership of the veterinary diagnostics firm.

Why it matters

IDEXX Laboratories is a leading provider of diagnostic products and services for the animal health, water testing, and food safety markets. The substantial increase in ownership by a major institutional investor like Congress Asset Management suggests growing confidence in the company's long-term growth prospects within the veterinary industry.

The details

Congress Asset Management Co. purchased an additional 152,368 shares of IDEXX Laboratories during the fourth quarter, bringing its total stake in the company to 153,908 shares worth $104.1 million. This represents a 9,894% increase in the fund's position compared to the prior quarter. IDEXX Laboratories is known for its innovative point-of-care diagnostic instruments, reference laboratory testing services, and practice management software used by veterinarians worldwide.

  • Congress Asset Management Co. disclosed the increased stake in IDEXX Laboratories in a 13F filing with the SEC on March 24, 2026, covering the fourth quarter of 2025.

The players

Congress Asset Management Co.

A Boston-based investment management firm that oversees over $20 billion in client assets.

IDEXX Laboratories, Inc.

A global leader in veterinary diagnostics, water testing, and food safety solutions, headquartered in Westbrook, Maine.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in institutional ownership of IDEXX Laboratories by a major asset manager like Congress Asset Management suggests growing confidence on Wall Street in the company's ability to capitalize on long-term trends in the veterinary diagnostics market.